Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 9/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481366 | 0.84 | PTGS2 (0.48) | PTGS2FTOCXCL8 | |
| SCHEMBL22481034 | 0.78 | PTGS2 (0.46) | PTGS2FTOCXCL8ALDH1A1KDM4E | |
| SCHEMBL24021600 | 0.78 | FTO (0.77) | FTO | |
| SCHEMBL23831486 | 0.76 | DHODH (0.65) | ALDH1A1KDM4EMAPTHTT | |
| SCHEMBL27750343 | 0.76 | NPC1 (0.68) | ALDH1A1KDM4EMAPTHTTCASP1 | |
| SCHEMBL13143940 | 0.74 | PTGS2 (0.53) | PTGS2CXCL8ALDH1A1KDM4E | |
| SCHEMBL13679149 | 0.74 | PTGS2 (0.58) | PTGS2CXCL8 | |
| SCHEMBL8894839 | 0.74 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTHTTCASP1 | |
| SCHEMBL1202680 | 0.74 | ULK1 (0.53) | PTGS2 | |
| SCHEMBL10748316 | 0.73 | CRBN (0.56) | ALDH1A1KDM4EMAPTHTTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308102-A1 | MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308102-A1 | MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF | TRPV1, TRPV2, TRPV5 | PTGS2 573/4885FTO 3681/4885CXCL8 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.